Compare KWR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | SRPT |
|---|---|---|
| Founded | 1918 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 1994 | 2000 |
| Metric | KWR | SRPT |
|---|---|---|
| Price | $144.46 | $15.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 29 |
| Target Price | ★ $167.00 | $25.85 |
| AVG Volume (30 Days) | 119.0K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.13 | ★ 2.88 |
| Revenue | $1,888,634,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $126.96 | ★ $5.21 |
| Revenue Growth | 2.66 | ★ 15.58 |
| 52 Week Low | $111.42 | $10.42 |
| 52 Week High | $183.01 | $25.32 |
| Indicator | KWR | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 34.08 |
| Support Level | $128.25 | N/A |
| Resistance Level | $145.30 | $23.54 |
| Average True Range (ATR) | 4.92 | 0.73 |
| MACD | -0.25 | -0.06 |
| Stochastic Oscillator | 64.85 | 15.56 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.